FDA July 2026 Update: Comprehensive Enforcement Action Against Synthetic 7-OH Products

Why it matters

The FDA's consolidated 7-OH resource hub — updated July 13, 2026 — gives clinicians, consumers, and policymakers a single authoritative reference for understanding federal enforcement actions against concentrated synthetic kratom products, including how to report adverse events and when the public comment window closes.

The big picture

Since July 1, 2026, the FDA, DEA, and HHS have been running a coordinated multi-agency response to the rapid growth of concentrated 7-OH products sold in gas stations, smoke shops, and online. The FDA has issued warning letters, supported DEA scheduling actions, directed physical product seizures, and coordinated with state health agencies. The hub page consolidates all of these actions and consumer advisories in one location, and makes clear that naturally occurring trace-level 7-OH in botanical kratom leaf is not the target.

Key findings

• On July 1, 2026, the DEA published a Notice of Intent to temporarily place 7-OH above a specified threshold in Schedule I, along with three fully synthetic 7-OH derivatives: mitragynine pseudoindoxyl, MGM-15, and MGM-16
• HHS simultaneously opened a 30-day comment period — docket HHS-OASH-2026-0232 — soliciting data on what 7-OH concentration constitutes an imminent public safety hazard; the window closes July 31, 2026
• The scheduling action explicitly does not apply to botanical kratom containing naturally occurring trace-level 7-OH below the threshold
• FDA previously coordinated seizure of approximately 73,000 units of concentrated 7-OH products valued at ~$1 million from three Missouri firms
• FDA has issued warning letters to companies marketing 7-OH in foods, dietary supplements, gummies, drink mixes, and shots — products that cannot lawfully contain this ingredient

What they say

"This enforcement action is a strong step to protect Americans from the dangers of concentrated 7-OH products, which are potent opioids." — FDA Commissioner Marty Makary, M.D., M.P.H.

Bottom line

The FDA's July 2026 enforcement posture draws a clear regulatory line between natural kratom leaf and concentrated synthetic 7-OH — and anyone with safety threshold data has until July 31 to submit it to HHS at docket HHS-OASH-2026-0232.